In 2011 the US pharmaceutical industry spent over $1b on on-line marketing. In social media, however, uncertainty has reigned as to what is permissible for the sector. So when the Food & Drug Administration issued draft guidelines, there were high hopes of greater clarity. Nick Johnson sees if these were justified.
